Zanzalintinib maintenance for high-grade neuroendocrine tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called zanzalintinib as a maintenance therapy to keep high-grade neuroendocrine tumors from growing after chemotherapy. It may be a good option if you've had success with chemotherapy and are ready for a treatment break.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a high-grade neuroendocrine tumor (a fast-growing type of cancer from hormone-producing cells).
- You have completed at least 2 rounds of chemotherapy and your most recent scan showed your tumor is stable or smaller.
- You are 18 or older and able to do daily activities with little help.
- Your blood counts, liver, and kidney function are within certain limits.
- You haven't taken zanzalintinib or cabozantinib before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a maintenance therapy combining zanzalintinib and etoposide after you've completed high-dose chemotherapy and a stem cell transplant for germ cell cancer. The goal is to see if this drug combination helps prevent the cancer from coming back.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
This trial compares a new targeted therapy (zanzalintinib) with an existing drug (everolimus) for people with advanced neuroendocrine tumors (NETs). It aims to see which treatment works better and may offer a new option for patients whose cancer has grown despite previous treatments.
This trial tests a drug called Zanzalintinib for people with meningioma that has come back or grown despite past treatments. It aims to see if the drug can stop or slow tumor growth.
This trial tests an oral drug called zanzalintinib in people with pheochromocytoma or paraganglioma that has spread or cannot be removed by surgery and has gotten worse. The goal is to see if the drug can slow or stop tumor growth.
This trial tests a new drug called zanzalintinib for people with advanced bladder cancer that has worsened after previous treatments. The goal is to see if zanzalintinib can help control the cancer.
Hear when a new High Grade Neuroendocrine Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.